Skip to main content
. 2025 Jul 21;13(4):97. doi: 10.3390/pharmacy13040097
BC Breast cancer
ADR(s) Adverse drug reaction(s)
DDI Drug–drug interaction
QOL Quality of life
BSE Breast self-examination
RCT Randomized controlled trial
MTM Medication therapy management
CMM Comprehensive medication management
OHT Oral hormonal therapy
QALYs Quality-adjusted life years
ER Emergency room
DRP Drug-related problem
CSI Clinically significant interactions
CDTM Collaborative drug therapy management
CAIT Cancer and Aging Interdisciplinary Team
CB-PCT Consultation-Based Palliative Care Team
EPR Electronic patient record
AET Adjuvant endocrine therapy
CDK4/6i Cyclin-dependent kinase 4/6 inhibitor
COVID-19 Corona Virus Disease 2019
HFS Capecitabine-related hand–foot syndrome
AEs Adverse events